Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Polycarbophil calcium

Drug Profile

Polycarbophil calcium

Alternative Names: AHR 3260B; Calcium polycarbophil; Colonel; Equalactin; FiberCon; HSR 237; Mitrolan; Polyful; Wl 140

Latest Information Update: 29 Jan 2013

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Abbott Japan
  • Developer Abbott Japan; Astellas Pharma
  • Class Antidiarrhoeals; Irritable bowel syndrome therapies; Laxatives; Polymers
  • Mechanism of Action Undefined mechanism
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • Marketed Irritable bowel syndrome
  • Discontinued Diarrhoea

Most Recent Events

  • 24 Jun 2018 Biomarkers information updated
  • 30 May 2005 Clinical trials in Diarrhoea in Japan (PO)
  • 30 May 2005 Data presented at the Digestive Disease Week-2005 conference (DDW-2005) have been added to the Digestive system disorders therapeutic trials section
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top